Remove Biosimilars Remove Drug Research Remove Production
article thumbnail

Drug Channel Implications of the Inflation Reduction Act (NEW Live Video Webinar)

Drug Channels

The potential effect of the IRA on manufacturers’ new drug research and development strategies is beyond the scope of this webinar. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. The webinar will last 90 minutes to accommodate audience questions.

article thumbnail

Innovation Drives Excellence, Innovent Successfully Held 2020 Virtual R&D Day

The Pharma Data

Growing into a biopharmaceutical company, Innovent has built an integrated platform covering from drug discovery, CMC, clinical development and commercialization. In addition, in order to achieve next level strategic goal of developing global first-in-class product in 5-10 years, Innovent Academy has been established.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article EMA Thank You What will the orphan drug market exclusivity haircut mean for industry?

Agency IQ

The Orphan Regulation entered into force in January, 2000, outlining requirements for orphan designation and incentives, and establishing the EMA Committee for Orphan Medicinal Products (COMP). Unmet medical need requires the disease to remain associated with high morbidity or mortality if a product is approved for that condition.

article thumbnail

Article EMA Thank You What we expect European regulators to do in August and September 2024

Agency IQ

Additionally, the EMA plans to launch further feature of the SPOR (substance, product, organizational, referential) services. The suite of services aims to harmonize the identification of medicinal products and is being rolled out in an iterative fashion.